To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found signifi cant tissue and tumor subtype-specifi c differences in multiple cell types including T cells and neutrophils. Gene expression profi ling of CD45 T-cell receptor clonotype diversity was signifi cantly higher in DCIS than in IDCs. Immune checkpoint protein TIGIT-expressing T cells were more frequent in DCIS, whereas high PD-L1 expression and amplifi cation of CD274 (encoding PD-L1) was only detected in triple-negative IDCs. Coamplifi cation of a 17q12 chemokine cluster with ERBB2 subdivided HER2 + breast tumors into immunologically and clinically distinct subtypes. Our results show coevolution of cancer cells and the immune microenvironment during tumor progression.
Most prior analyses of leukocytes in breast tumors, especially in DCIS, have been limited to inferring leukocyte composition from gene expression profiles of bulk tumors (6) (7) (8) (9) (10) and to the testing of a handful of markers in archived tissue samples (11) (12) (13) (14) (15) (16) . Thus, our understanding of immune-related changes in early stages of breast tumorigenesis is still rather limited.
Here we used a combination of global profiling and singlecell methods for the cellular and molecular characterization of tissue-infiltrating leukocytes, with particular emphasis on T cells, in normal breast tissues, pure DCIS (no histologic evidence of invasion), and in HER2
+ and triple-negative (TN) invasive ductal breast carcinomas. We also characterized genetic alterations in cancer cells that might affect the tumor immune microenvironment and disease progression. Our goal was to gain insights into the coevolution of tumor and immune cell compartments during the in situ to invasive carcinoma transition. We focused on HER2 + and triple-negative tumor subtypes, as these DCIS have a higher risk of invasive recurrence and the resulting invasive tumors are also more likely to progress to metastatic disease.
ResUlts

Leukocyte Composition of Human Breast Tissues
We first characterized the composition of tissue-infiltrating leukocytes in normal and neoplastic breast tissues using a polychromatic FACS, which allows for the quantitative assessment of all major leukocyte cell populations (ref. 14; Fig. 1A ; Supplementary Fig. S1A ). Quantification based on FACS was reproducible and accurate as confirmed by the analysis of the same tumor stained and profiled separately and by comparing it to histologic examination of tissue slides (Supplementary Fig. S1B and S1C). We analyzed normal breast tissues from nulliparous and parous women, including BRCA1 and BRCA2 mutation carriers, as well as DCIS and invasive ductal carcinomas (IDC) of different subtypes (Supplementary  Table S1 ). In normal breast tissues, we analyzed epithelial and stromal fractions separately to detect potential differences between intraepithelial and stromal leukocytes. We found that DCIS and IDC contained significantly (P = 0.0015 and P < 0.0001, respectively) higher numbers of leukocytes, compared with normal breast, whereas in normal tissues, more leukocytes were in the stromal than in the epithelial fraction (Fig. 1B) . We also observed significant differences in the relative frequencies of several CD45 + cell types, including increased neutrophils and decreased CD8 + /CD4 + T-cell ratios in tumors compared with normal stroma ( Fig. 1A and C; Supplementary Table S2 ). The relative fraction of CD8 + and CD4 + T cells showed significant inverse correlation in normal breast tissues and DCIS, and in DCIS higher fractions of CD8 + T cells were associated with significantly higher frequency of macrophages ( Supplementary Fig. S1D ). The frequencies of dendritic cells and T cells showed significant inverse correlation in TN IDCs ( Supplementary Fig. S1D ), whereas the relative proportion of γδ T cells was significantly higher in IDCs compared with normal breast tissues (P = 0.008) and DCIS (P = 0.0476; Supplementary Fig. S1E ). This latter result is potentially interesting in light of recent findings in animal models showing that γδ T cells promote breast cancer metastasis via their recruitment of neutrophils (17) . Corroborating this, we detected higher fraction of neutrophils in IDCs compared with normal breast tissues (Fig. 1C) . However, the clinical relevance of γδ T cells in human breast tumors is inconclusive; some studies suggest that their frequency is associated with good prognosis (18) , whereas others show that their higher frequency indicates poor outcome (19) . Overall, these changes in leukocyte composition imply a switch to a more immunosuppressive and metastasis-promoting environment during breast tumor progression. We focused our subsequent analyses on T cells due their central role in immune responses and being the most dominant CD45 + cell population in both normal and cancerous breast tissues. Next, we performed multicolor immunofluorescence for CD45 pan-leukocyte and CD3 T-cell markers to assess the spatial distribution of leukocytes within normal and neoplastic breast tissues. We also stained for smooth muscle actin (SMA) to mark myoepithelial cells surrounding the ducts; intact myoepithelial cell layer and basement membrane are detected in normal breast and in DCIS but lost in invasive breast carcinomas. In normal breast tissues there were relatively few T cells, with the exception of mastitis or other benign inflammation, and minor differences were observed between nulliparous and parous women ( Fig. 1D ; Supplementary Fig. S1F and S1G). In DCIS, we found significantly higher fraction of T cells in high-grade compared with lowgrade DCIS (P < 0.0001), and HER2
+ compared with HER2 − DCIS (P < 0.0001), and DCIS adjacent to IDC also contained significantly (P = 0.0002) higher frequency of T cells than pure DCIS ( Fig. 1E and F) . However, the spatial distribution of T cells was highly variable in DCIS; some areas of the tumor had very high leukocyte and T-cell density, whereas others contained almost none (Fig. 1E) . In several DCIS, we even detected probable tertiary lymphoid structures (TLS; ref. Cancer Research.
on November 2, 2017. © 2017 American Association for cancerdiscovery.aacrjournals.org Downloaded from www.aacrjournals.org their numbers being relatively low (Fig. 1D) , in contrast to DCIS where T cells were rarely detected within the ducts but rather localized in the stroma and at sites of focal myoepithelial cell layer disruption (Fig. 1E) . These findings suggest that in DCIS there is limited interaction between T cells and cancer cells; thus, immune escape is most likely to occur during in situ to invasive carcinoma transition.
Gene Expression Profiles of CD3
+ T Cells
To begin dissecting the properties of T cells infiltrating normal and neoplastic breast tissues, we performed RNA sequencing (RNA-seq) on purified CD45 +
CD3
+ T cells from normal breast tissues (n = 12), DCIS (n = 11), and IDC (n = 12), focusing on HER2 + (n = 5), and TN (n = 6) IDC cases (Supplementary Table S1 ). In normal breast tissues, parity and BRCA status did not appear to influence T-cell gene expression profiles; thus, we considered all normal samples as one group. Principal component analysis (PCA) of T-cell gene expression profiles demonstrated separation of normal samples from DCIS. Although the HER2 + IDCs were more similar to normal cases, TN IDCs clustered with DCIS ( Fig. 2A and B). Unsupervised hierarchical clustering of the samples using differentially expressed immune-related genes showed a clear separation of T cells from normal breast, DCIS, and HER2 + and TN IDC, indicating that these groups have largely distinct T-cell expression profiles ( Fig. 2B ; Supplementary Table  S3 ). The most abundantly expressed genes were related to T-cell receptor (TCR) signaling (e.g., NFATC1, NFKB1) and antigen presentation (e.g., HLA-A, HLA-C), which appeared to be more highly expressed in normal samples. Transcriptional regulators of T cells (e.g., TBX21, GATA3) were somewhat consistently expressed among samples with the exception of EOMES, which had low expression in T cells from TN IDC, and FOXP3, which was more abundant in T cells from IDCs (both HER2 + and TN cases). IL18R1, CXCL13, CXCL1, and CTLA4 were also more abundant in T cells from IDCs than in DCIS, whereas the expression of ILF3 and NFKBIA and several interleukin receptors (e.g., IL2RA, IL10RA) was higher in T cells in DCIS and normal breast than in IDCs. TNFRSF25 and other TNF receptors were more highly expressed in DCIS-associated T cells compared with normal breast and IDCs, whereas LCK kinase, which is involved in T-cell development and TCR signaling, showed the opposite pattern; these results were also confirmed by immunofluorescence analysis ( Supplementary Fig. S2A ). Gene set enrichment analysis (GSEA) using the canonical gene set compendium (21) showed that, as expected, immune-related gene sets were enriched in our list of significantly differentially expressed genes (Supplementary Fig.  S2B ; Supplementary Table S4 ). This included a downregulation of genes in the IL4 signaling pathway in IDC and normal samples compared with DCIS. Furthermore, the Th1Th2 and CTLA4 signaling pathways were upregulated in IDC compared with DCIS, and the complement pathway was higher in normal compared with DCIS samples. Differences between HER2
+ and TN IDC included the upregulation of pathways signaling through IL6, IL7, CTLA4, and antigen presentation by MHC I in TN cases (Supplementary Table  S4 ). Also enriched were gene sets corresponding to cell signaling pathways, transcription and translation, and cell cycle in the HER2 + /TN IDC comparison, suggesting potential T-cell expansion. Overall, these results suggest a more inflammatory and more immunosuppressive environment in IDCs compared with DCIS, especially in TN tumors.
To obtain a more detailed view of the specific activities of T cells, GSEA was conducted using ImmuneSigDB (21), a compendium of gene signatures summarizing differences between two given groups of immune cells. First, we summarized enriched gene sets according to the frequency of a particular immune lineage and compared with the overall frequency of that given cell type appearing in the compendium (Fig. 2C) TNFRSF1B  ILF3  CXCL13  TAF12  IL18R1  SIAH1  MASP2  SUGT1  CCDC88A  LEP  NR1H3  DUOX2  SEMA7A  TNFRSF25  FGFR4  RABEP2  ZBP1  SLAMF1  PTGES2  ARHGEF2  CXCL1  GLI1  APOBEC3G  TAF6  NEO1  ILK  CMTM7  DCN  HDAC2  RPS6KA5  NMT2  ADM  HBEGF  ADAM10  CDC42  ATF3  CACYBP  ROCK2  PSMD8  ATP6V0D1  CTLA4  PML  PSMC3  NLRC5  LIMS1  PSTPIP1  TMPRSS6  BMP8A  ERN1  NLRC3  MID2  VPS37B  TXLNA  IL10RA  PIK3R5  PTK2B  GNB1  GRK5  HDGF  ID2  IL2RB Fig. S2D ). Nevertheless, further experimental validation of these predictions is needed.
Activation of CD8 + T Cells in DCIS
The enrichment of DCIS T-cell expression profiles for CD8 + T-cell signatures and the predicted higher frequency Fig. S3E ). Importantly, analysis of matched DCIS and IDC samples in a cohort of patients who were diagnosed with pure DCIS and underwent lumpectomy, but years later recurred locally with IDC, demonstrated the same results ( Fig. 3E-H ), confirming that a decrease in activated CD8 + T cells is a feature of in situ to invasive breast carcinoma progression.
To further explore the potential clonal expansion of T cells in DCIS, we aligned our RNA-seq data to a library of known variable human complementarity determining regions (CDR) to determine the frequency of unique TCR segments in each sample (23) . Samples were normalized on the basis of the relative fraction of T cells. The TCR is rearranged during T-cell maturation, and a population of T cells that have the same unique TCR sequence is defined as a TCR clonotype. TCR clonotype repertoire can be quantitatively assessed using the Shannon index of diversity (24) . DCIS cases overall appeared to have more clonally expanded T cells than IDCs ( Supplementary Fig. S4A ), and TCR clonotype diversity measured by the Shannon index was significantly (P = 0.03) higher in DCIS compared with IDCs (Fig. 3I) . The correlation between MKI67 read counts and the Shannon index of TCR clonotype diversity was the highest in TN IDCs, implying the expansion of multiple T-cell clones in these tumors ( Supplementary Fig. S4B ). Similar positive correlation was observed in TN IDCs between the expression of T-cell activation markers (e.g., GZMB, PRF1, and CCL4) and TCR clonotype diversity ( Supplementary Fig. S4C ), further implying the presence of polyclonal activated T cells. In contrast, the generally lower TCR clonotype diversity in HER2
+ cases might reflect expansion of a limited set of T-cell clones. As an alternative method to assess the TCR repertoire in DCIS, we performed immunoSEQ that defines TCR clonotype diversity based on DNA sequence (25) . ImmunoSEQ also showed polyclonality in all DCIS, although a few dominant clones were also detected, and the top 10 most abundant clones in each case revealed differences among samples (Supplementary Fig. S4D and S4E). Similarly, clustering of samples based on normalized frequencies of TCR v and j genes highlighted several similarities and differences among samples (Supplementary Fig. S4F and S4G). The two samples for which we had both RNA-seq and immunoSEQ data (DCIS15 and DCIS17) appeared to have the highest fraction of expanded clones based on TCR and were also highly MKI67 + and GZMB + . Interestingly, we found a few TCR clones that were shared (at the amino acid level) among different tumors and represented relatively more abundant clones ( Supplementary  Fig. S4H ). For one of these TCRs, we were able to predict the putative antigen as EBNA3, an Epstein-Barr virus protein based on prior TCR repertoire analyses (26) . The presence of shared, relatively prominent clones, in combination with our RNA-seq data, support the possibility of an adaptive immune response in a subset of DCIS and a potential decline of this after progression to IDC.
Immune Checkpoint Proteins
Our observation that IDCs, particularly TN IDCs, contained relatively more TILs but fewer in the activated state than DCIS implied potential exhaustion and immunosuppression in IDCs. To investigate this hypothesis, we analyzed our RNA-seq data for genes characteristic of exhausted state, including genes encoding for immune checkpoint proteins (e.g., CTLA4, PD-1, TIGIT; Supplementary Table S5) . We found a positive correlation between exhausted and cytotoxic gene signatures in both MKI67 hi and MKI67 lo T cells, which was expected as these markers are commonly coexpressed in the same T-cell population and exhaustion is usually due to chronic activation. On the other hand, the expression of inhibitory and activating immune checkpoint proteins showed positive correlation only in MKI67 hi T cells (Supplementary Fig. S5A and S5B) . Similarly, the expression of T-cell activation and dysfunction-related genes (27) was significantly different in tumor-associated MKI67 hi and MKI67 lo T cells (Supplementary Fig. S5C ).
Cancer Research. To explore the expression of immune checkpoint proteins in further detail, we performed immunofluorescence analysis for TIGIT, PD-1, and PD-L1 in DCIS and IDCs, as these proteins have been previously implicated in breast cancer with clinical trials targeting them currently ongoing (Fig. 4A-C) . TIGIT was expressed mostly in CD3 + T cells but also in other leukocyte populations ( Fig. 4A; Supplementary Fig. S5D ). In contrast, PD-L1 expression was more widespread with high expression in various immune cells and in a subset of tumor epithelial cells ( Fig. 4B; Supplementary Fig. S5E ). In a luminal A IDC with an extensive in situ region, PD-L1 was highly expressed in DCIS-associated myoepithelial cells but not in tumor cells, whereas in the invasive areas, the tumor epithelial cells were highly PD-L1-positive ( Supplementary Fig. S5F ). This finding implies that in DCIS, myoepithelial cells might play a role in immune suppression and tumor epithelial cells that gain this phenotype have a selective advantage during invasive progression. TIGIT and PD-1 were also frequently coexpressed in CD8 + T cells in both DCIS and IDCs (Fig. 4C) , similar to what was described in melanoma (28 Fig. S5G ). In a few cases, we analyzed the expression of TIGIT by both FACS and immunofluorescence to confirm our results, and we detected similar TIGIT levels by both techniques ( Supplementary Fig. S5H ). We also analyzed the spatial distribution of TIGIT + or PD-1 + CD3 + T cells to see potential (Fig. 4B) . These results imply potential differences in the microenvironment such as the extracellular matrix (ECM) or differences in local myeloid complexity of HER2 + and TNBCs that could influence the ability of T cells to invade tumors and enter the ducts. Correlating with this finding, collagen trichrome staining showed some differences between HER2 + and TNBCs, especially in DCIS, with HER2 + DCIS displaying a denser fibrous ECM potentially forming a physical barrier (Supplementary Fig. S6C ).
The high expression of PD-L1 in tumor epithelial cells in TN IDCs (Fig. 4B ) raised the possibility of specific upregulation of PD-L1 in these tumors due to copy-number gain, as we and others previously described that a 9p24 amplicon including CD274 (encoding for PD-L1), PDCD1LG2 (encoding PD-L2), and JAK2 occurs only in basal-like breast tumors where approximately 30% of cases have a high copy-number gain of this region (29, 30) . To investigate this hypothesis in more detail, we examined the frequency of gains and losses of the CD274 locus in The Cancer Genome Atlas (TCGA) cohort composed of invasive breast cancers, and found an enrichment of gains in the basal subtype of approximately 40% (P < 0.001 χ 2 test, Fig. 4E ; Supplementary Fig. S7A-S7C ). 9p24 copy-number gain was not associated with any differences in cytotoxic T-cell gene signatures, probably due to the expression of PD-L1 by many stromal cell types besides tumor epithelial cells (Supplementary Fig. S7D ). 9p24 gain was also independent of neoantigen load and estimated immune content, but was associated with overall copy-number aberration (CNA) status only in TN cases (Supplementary Table S6 ). Similar comparisons in the Oslo cohort (9) that included both DCIS and IDCs reported a higher frequency of CD274 and PDCD1LG2 gain in IDC samples (6/12 patients) compared with DCIS (2/9 patients), which had basal-like expression profiles (Fig. 4E) . To confirm the preferential gain of CD274 and overexpression of PD-L1 in TN IDCs compared with DCIS, we developed an immuno-FISH protocol that allows for the combined analysis of PD-L1 protein levels and CD274 copy-number status at the single-cell level in archived samples. Testing of 10 TN IDCs revealed CD274 copy-number gain and PD-L1 overexpression in 3 of 10 cases, whereas none of the 10 TN DCIS showed gain of this locus and had relatively low expression of PD-L1 (Fig. 4F ). These results suggest a possible mechanism for the in situ to invasive breast carcinoma transition in TNBC through the selection for tumor cells with higher expression of PD-L1 due to increased copy number for CD274. The clinical relevance of these findings as they relate to the likelihood of response to PD-L1 blockade remains to be determined.
17q12 Chemokine Amplicon
To explore whether other genomic regions encoding for genes involved in immune regulation may also display differential copy-number gain between DCIS and IDCs, we analyzed known breast cancer amplicons for the presence of such genes. We found that the 17q12 chromosomal region that contains a cluster of genes encoding chemokines is located proximal to the ERBB2 amplicon, making it prone to possible coamplification (Fig. 5A) . Interestingly, in the TCGA Table S7 ). The magnitudes of elevation of probability of chemokine cluster amplification in HER2 on November 2, 2017. © 2017 American Association for cancerdiscovery.aacrjournals.org Downloaded from cohort, chemokine cluster (CC) gain was associated with ERBB2 amplicon status independent of immune content and overall CNA but was negatively associated with neoantigen load, suggesting coamplification as an alternate mechanism for immune activation (Supplementary Table S6 ). An enrichment of CC gains was observed in HER2 + tumors defined either by PAM50 classification or ERBB2 amplification (50% compared with 2%, P < 0.001 χ 2 test; Supplementary Fig.  S7E ). Interestingly, these HER2
+ tumors can roughly be divided into two groups: those which are HER2 + ER + luminallike and display evidence of coamplification, and those which are HER2 + ER − as defined by PAM50, which do not exhibit coamplification and in fact suggest loss of this locus (Fig. 5B) . To assess whether the copy-number gain of this locus is associated with changes in leukocyte composition, we analyzed the expression of immune activation and exhaustion-related genes in these samples and found higher expression of both activation and inhibition-related genes in tumors that lack CC gain (Fig. 5C) 
ER
+ tumors with gain of the CC region.
Next, we developed a multicolor FISH assay to evaluate both the 17q12 CC and ERBB2 copy-number gain in HER2 + IDCs and DCIS at the single-cell level ( Fig. 5D ; Supplementary Table S7 ). Adjacent slides were used for immunofluorescence to assess T-cell frequency and activation. We found that cancer cells with ERBB2 gain had significantly higher chance of gaining the CC locus, especially in pure DCIS cases ( Fig. 5E ; Supplementary Table S7) . Analysis of the intratumor spatial distribution of cells with or without CC gain did not reveal any specific pattern in DCIS nor in IDC ( Supplementary Fig. S7F and S7G ). The Shannon index of diversity for CC and ERBB2 copy numbers did not display significant correlation with frequencies of CD3 + T cells and CD45 + leukocytes, neither in pure DCIS nor in DCIS/IDC cases ( Supplementary Fig. S7H ). However, CC amplification showed significant inverse correlation with the frequency of GZMB + CD8 + T cells within tumors (Fig. 5F ). Moreover, we found a relatively strong positive correlation between the Shannon index and patient age at diagnosis in HER2 + IDC cases but not in pure DCIS (Supplementary Fig. S7I ). To investigate whether the decreased T-cell activation in tumors with CC gain might be due to higher frequencies of myeloidderived suppressor cells (MDSC), we stained adjacent slides for CD68, CD33, and HLA-DRB1 that allow for the detection of macrophages (CD68 Fig. S7J ). However, the numbers of macrophages and MDSCs did not correlate with CC copy number or fraction of GZMB +
CD8
+ T cells (Supplementary Fig. S7K and S7L) , suggesting other mechanisms underlying the "immune cold" status of these tumors. Finally, a generalized linear model predicting CC coamplification (Supplementary Table S7 ) suggested an association between ERBB2 and ER, consistent with our findings from the TCGA cohort (Fig. 5B) . These results imply potential selection for cancer cells that have lost the 17q12 CC amplicon during DCIS to IDC progression only in HER2 
DiscUssiON
Evasion of immune surveillance is a necessary step in tumor evolution. Despite its importance, our understanding of mechanisms of immune escape in human tumors is rather limited. In DCIS, the tumor cells are relatively protected from the immune system due to an intact myoepithelial cell layer and basement membrane, and intraductal T cells are rarely detected (Fig. 6) . In contrast, in invasive disease, cancer and immune cells are intermingled. Thus, the in situ to invasive carcinoma transition might be a particularly important bottleneck for immune escape and tumor evolution, and the analysis of this could identify novel targets for immunotherapies, which has had limited success so far in patients with breast cancer (1, 31) . One reason for this limited success might be that different tumors evade the immune system via different mechanisms, and thus the identification and characterization of immune escape mechanisms is critical for the design of novel and more effective immunotherapies.
Here, we investigated potential mechanisms of immune escape in breast cancer by analyzing the composition and molecular profiles of leukocytes, with special emphasis on T cells, in normal breast tissues, DCIS, and IDC. Using clinical samples from normal and neoplastic breast tissues, we performed FACS analyses and RNA-seq on sorted T cells. As tissue dissociation can influence the number of viable cells recovered and may also affect the detection of some antigens (the relatively high fraction of Lin − cells in our FACS may be due to this), we also tested selected genes by immunofluorescence on intact tissue sections. Using these approaches, we determined that T cells in DCIS are enriched in activated effector CD8 + T cells characterized by the expression of GZMB and MKI67, but the frequencies of these cells decreases in invasive disease. This was particularly evident in DCIS cases that recurred locally as IDC, implying that decreased immune activity may be necessary for invasive progression. Currently there are no clinically useful biomarkers that would predict the risk of invasive progression of DCIS, and considering that approximately 40,000 women are diagnosed annually with DCIS in the United States alone, this is an important clinical problem. Our data suggest that the frequency of activated CD8 + T cells may predict which DCIS is likely to progress to invasive disease. Analysis of the TCR repertoire also displayed significantly higher clonotype diversity in DCIS compared with IDCs, and we identified several more prominent shared clones among cases. Interestingly, one of these TCRs was predicted to react to an epitope in EBNA3, an Epstein-Barr virus protein. This finding does not necessarily imply a casual role for the Epstein-Barr virus in breast cancer, but it is consistent with a hypothesis that some T cells reactive to commensal microflora and common infectious agents may cross-react with some tumor neoantigens (32) . However, further studies are required to test this hypothesis. Several immune checkpoint proteins displayed significant differences between DCIS and IDC, particularly in TN cases. TIGIT + T cells were more common in DCIS than in IDC, especially in the TN subtype, whereas the expression of PD-L1 was almost undetectable in DCIS tumor epithelial cells but increased to higher levels in IDC with the amplification of the CD274 locus encoding PD-L1 in a subset (∼30%) of the cases. In Hodgkin lymphoma, the presence of this same 9p24.1 amplicon is highly predictive of response to PD-1 blockade (33), raising the possibility that this might also be the case in TNBCs, but this remains to be explored. The expression of CTLA4 was also higher in T cells from IDCs compared with DCIS, further supporting the development of a suppressive immune microenvironment during invasive progression. The changes in the expression of these immune checkpoint proteins during DCIS to IDC transition suggest that the application of immunotherapies can be and may actually be more effective at earlier stages compared with metastatic disease. This hypothesis is supported by findings in animal models showing that the most efficient antitumor immune response was achieved when primary tumor and draining lymph nodes were still present (34, 35) . Thus, it would be useful to test whether immunotherapy could be more effective in breast cancer when applied in the neoadjuvant phase in combination with chemotherapy. Most prior studies analyzing leukocytes and the prognostic value of TILs in breast cancer have focused on invasive tumors, whereas DCIS and premalignant lesions have been relatively neglected. This is in part due to difficulties with obtaining fresh tissue samples from these small preinvasive lesions that are required for comprehensive profiling studies, and also due to the focus on advanced-stage disease that is subject to systemic therapies including immunotherapy. Previous genomic characterization of DCIS cases has identified gene expression signatures implying the presence of activated T cells in a subset of tumors (8) , but this was not confirmed by any other method. Prior studies have also shown that the frequencies of Tregs increased during tumor progression, suggesting that this could be used to predict risk of invasive progression (13) . However, in our experience the frequency of FOXP3 + T cells is very low in DCIS (<10% of T cells) and their topologic distribution is highly variable within tumors, making their assessment inaccurate in thin tissue sections (see Supplementary Methods). In contrast, activated GZMB + CD8 + and Ki67 + CD8 + T cells were very common within DCIS, implying that they could potentially be better biomarkers for predicting risk of invasive progression. Our observation that the frequency of these cells is decreased in local invasive recurrence of DCIS supports this hypothesis, but further testing in large, uniformly treated cohorts with long-term follow-up would be required to determine this. + tumors. Interestingly, the copy-number gain was relatively low in a subset of luminal HER2 + tumors for both ERBB2 and the CC locus, which could imply higher intratumor heterogeneity in these tumors that can contribute to their lower response rate to HER2-targeted therapies. The lower frequency of TILs and particularly fewer activated GZMB + CD8 + T cells in these luminal HER2 + IDCs could further increase the probability of treatment resistance, as the presence of these cells is associated with better response to both chemotherapy and HER2-targeted therapies. Because of the high number of chemokines in this 17q12 cluster and their diverse function, dissecting the mechanism by which coamplification of this locus affects T-cell activity would require more detailed functional studies in the future.
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Immunoediting is a key step in tumor evolution that can be divided into elimination, equilibrium, and escape phases (36) . Our data suggest that in DCIS, due to a mostly intact basement membrane and myoepithelial cell layer, relatively few cancer cells are exposed to immune cells and these can be mostly eliminated, keeping the tumor in the intraductal "equilibrium" stage. Because of subsequent selection for cancer cells that have lost (or never had) neoepitopes and/or upregulated immunosuppressive mechanisms, tumor cells escape from immune surveillance, and invasive and subsequent metastatic progression occurs. Therefore, the in situ to invasive breast carcinoma transition appears to be the most critical tumor progression step from both clinical and immunology standpoints. A better understanding of cellular and molecular changes that occur during DCIS to IDC transition could improve the design of immunotherapies for the treatment of both early-stage and advanced-stage disease. At the same time, our results also suggest that assessing the frequencies of activated CD8
+ T cells in DCIS may identify patients with high risk of invasive progression.
MethODs
Human Tissues and FACS
Fresh and archival formalin-fixed, paraffin-embedded (FFPE) tissue samples were obtained from Brigham and Women's Hospital/DanaFarber/Harvard Cancer Center, Sutter Health, Washington University (St. Louis, MO), Yonsei University Medical College Gangnam Severance Hospital (Seoul, Korea), and Seoul National University Bundang Hospital (Seoul, Korea). Samples were deidentified prior to transfer to the laboratory. All Institutional Review Boards approved the protocol and waived the informed consent requirement. Fresh human normal and neoplastic breast tissues were dissociated as described previously (37) . Polychromatic FACS was performed essentially as described previously (14) . Briefly, single-cell suspensions were blocked in PBS with 0.5% BSA and 2 mmol/L EDTA and stained at 4°C for 30 minutes with antibodies listed in Supplementary Table S8 . Live-Dead Aqua (Invitrogen) was used to eliminate dead cells from the analysis, and isotype control antibodies and unstained cells were used as negative controls. Single-antibody staining was used for gating controls. Cells were analyzed and sorted using BD LSR Fortessa cell analyzer and BD FACSAria II SORP UV (Becton Dickinson), respectively. For RNA-seq, EpCAM 
Histology and Immunofluorescence Analyses
Histology and multicolor immunofluorescence analyses were performed using 5-μm sections of FFPE tissues essentially as described previously (38) . Briefly, slides were deparaffinized in xylene and hydrated in a series of descending ethanol concentrations. After heat-induced antigen retrieval in either citrate (pH = 6) or TRIS-EDTA (pH = 9) buffer, the samples were permeabilized with 0.5% TritonX-100, blocked with 5% goat serum PBS, and sequentially costained with antibodies as indicated in Supplementary Table S8 . For TIGIT and CD33 staining, TSA indirect kit was used following the manufacturer's instructions (PerkinElmer). Image analysis was performed on 3 × 3 montage images acquired by Nikon Ti microscope attached to a Yokogawa spinning-disk confocal unit, 40 × Plan Apo objective, and OrcaER camera controlled by the Andor iQ software. Masson trichrome staining was performed as indicated by the manufacturer (American MasterTech). Myeloid suppressor cell classification and staining was performed as recommended by Bronte and colleagues (39) .
Multicolor FISH and Immuno-FISH
FISH to analyze ERBB2 and 17q12 chemokine cluster was performed using whole sections of FFPE breast tumor samples as described previously (38) . Briefly, 5 μm FFPE tissue sections on silylated glass slides were baked overnight at 70°C, dewaxed in xylene (Leica Microsystems), washed in 100%, 70%, and 50% ethanol (Leica Microsystems), rinsed with H 2 O, and air-dried for 1 hour. Tissue digestion was performed by treating the samples with 0.08% Pepsin in PBS (DAKO) at 37°C for 15-22 minutes. Afterward, the slides were washed in H 2 O, dehydrated in increasing concentrations of ethanol (50%, 70%, 85%, 100%), and air-dried. A FISH probe mix, containing ERBB2 BAC probe (RP11-94L15, provided by Drs. Hege Russness and Inga Rye, Oslo, Norway; labeled with SpectrumOrange dUTP by Nick Translation Kit; Abbott Molecular, according to the manufacturer's recommendations), CEP17Aqua probe (Abbott Molecular), and 17q12 chemokine cluster BAC probes (equal concentration of RP11-791G14 and RP11-278F22 cDNA; labeled with SpectrumGreen by Nick Translation Kit), was then applied to the slides, covered with coverslip, and sealed with rubber cement. Hybridization was performed for 7 minutes at 75°C followed by overnight incubation at 37°C in a humid chamber. Next, the slides were washed in 0.4× SSC with 0.3% NP-40 for 2 minutes at room temperature, in 0.4× SSC with 0.3% NP-40 for 2 minutes at 74°C, then in 2× SSC with 0.1% NP-40, in 2× SSC, and in PBS. Nuclear counterstaining was performed by 10-minute incubation at room temperature with 1 μmol/L To-Pro-3 in PBS (Molecular Probes, Life Technologies). After two additional washes in PBS and one in H 2 O, the slides were dried and mounted with Vectashield Mounting Medium (Vector Laboratories), covered with coverslips, and stored overnight to 3 days at −20°C. Different immunofluorescence images from multiple areas of each sample were acquired with a Nikon Ti microscope attached to a Yokogawa spinning-disk confocal unit, 40× plan apo objective, and OrcaER camera controlled by Andor iQ software.
For the detection of CD274 gene (encoding PD-L1) and PD-L1 protein, slides were deparaffinized and digested with Proteinase K for 20 minutes at 37°C before staining with PD-L1 antibody as described previously. Coordinates of imaged areas were recorded. After imaging, the same procedure as used for multicolor FISH was followed using CEP9 probe (Abbott Molecular) and BAC probe 599H20 (Life Technologies) labeled with SpectrumOrange dUTP by Nick Translation Kit (Abbott Molecular). After hybridization and washes, slides were mounted using Vectashield with DAPI (Vector Laboratories) and imaged using the set of coordinates from the first round of imaging. Images were then overlaid using R to compute overlaps and crop images. RNA-seq libraries were (single-end) sequenced using the Illumina NextSeq 500 Next Gen Sequencer. Datasets were aligned to the human reference GRCh37/hg19 genome using the STAR RNA-seq aligner (version STAR_2.5.1b; ref. 41) . Two-pass mapping was performed using the following modified parameters: -outSAMstrandField intronMotif, -outFilterMultimapNmax 20, -alignSJoverhangMin 8, -alignSJDBoverhangMin 1, -outFilterMismatchNmax 999, -outFilterMismatchNoverLmax 0.1, -alignIntronMin 20, -alignIntronMax 1000000, -alignMatesGapMax 1000000, -outFilterType BySJout, -outFilterScoreMinOverLread 0.33, -outFilterMatchNminOverLread 0.33, -limitSjdbInsertNsj 1200000, -chimSegmentMin 15, -chimJunctionOverhangMin 15, -twopassMode Basic. The read counts for individual genes were generated using the htseq-count script of the HTSeq framework (version 0.6.1p1; ref. 42) using modified parameters (-stranded no) and the hg19 refGene annotation file available at the UCSC Genome Browser. Genes were filtered to retain only those with at least 45 counts across all samples. Differential gene expression analysis was performed with both edgeR (43) and DESeq2 (44) using design models which take into account batch effects. For PCA and heat-map visualizations, counts were converted to log2(counts per million) and batch adjusted using limma (45) . Heat-map visualization was performed using the intersect of genes defined as differentially expressed using both edgeR and DESeq2, which also appear in the ImmPort database of immune-related genes (46) . Estimation of the relative proportions of different T cells was performed using CIBER-SORT (22) , using the author's gene signatures for members of the T-cell lineage and 100 permutations. Testing for significant differences among groups was performed using ANOVA.
RNA-seq and Data Analysis
GSEA
GSEA (47) was performed using the HTSAnalyzeR package (48) using a Benjamini-Hochberg corrected P value cutoff of 0.05 to define significant gene sets. Two gene set collections from MSigDB were assessed: (i) curated canonical pathways (c2) to determine whether immune-related gene sets were differentially expressed and (ii) immunologic signatures (c7) reflecting genetic perturbations or differences in cell states (21) . The c7 compendium contains 389 curated studies comparing differences in gene expression between cells of different lineages, or cells before and after treatment with specific chemokines. Thus, the multiple appearance of a gene set (e.g., Treg vs. CD4
in independent studies would strongly support a difference in phenotype. Enriched gene sets were summarized by: (i) the frequency of specific immune cell types (e.g., CD4
+ , CD8
+ , thymocytes) appearing as differentially expressed, with significance calculated using proportionality testing with correction for multiple hypothesis testing, and (ii) the corresponding directionality of these enriched gene sets in network diagrams. Node sizes in network diagrams were determined by the frequency of a given cell lineage appearing in the list of enriched gene sets. Edge weights were computed by the net number of gene sets supporting a link between cell types. For each network link, arrows are colored to highlight which group the test sample is more similar to (e.g., pink arrow in direction of CD4 T-cell suggests DCIS T cells are more similar to this phenotype) Immune signatures. A list of genes characteristic of T-cell activation, checkpoint inhibition, exhaustion, naïve T cells, activationspecific and dysfunction-specific were manually curated from the literature (refs. 23, 27, 49; Supplementary Table S4) . A score for cytotoxicity, exhaustion, naïve, checkpoint activation, and checkpoint inhibition was obtained for each sample by computing the mean logCPM value. To take into account differences in cell cycle, patients were grouped into "high" and "low" categories using a logCPM Ki67 threshold of −0.5.
TCR Alignment and Identification of Clonotypic T-cell Repertoires
The clonotypic repertoires of T cells have been identified by aligning the RNA-seq reads to the human CDR regions using MiXCR (default parameters), a tool specific for immunoglobulin (IG) and T-cell receptor profiling (50) . Only clonotypes with at least 2 reads were retained for further analyses. The clonotypes were then normalized using the number of sorted CD45 +
CD3
+ T cells used for the RNA-seq. The diversity of individual samples based on the number and abundance of different clonotypes is represented using the Shannon index (24) . The significance of the difference between DCIS, IDC, and normal samples based on clonotype diversity was calculated using the Wilcoxon rank sum test. For a comparison of the Shannon index of individual samples and also their subtypes to the expression of selected cytotoxic genes, the raw read counts of the genes have been normalized on the basis of library size using DESeq2 (44) .
Copy-Number Analyses
Copy-number log2 ratios were obtained from publicly available data from TCGA (51) and from the Oslo cohort (9) using Affymetrix SNP6 arrays with logR ratios adjusted for ploidy and tumor percentage using the allele-specific copy-number analysis for tumors (ASCAT) algorithm (52) . Copy-number data was truncated to lie within a [−2, 2] range. To allow for intratumor heterogeneity, a relaxed log2 ratio of ±0.3 was used to define gains and losses. In the TCGA cohort, HER2
+ patients were defined as positive either by PAM50 classification or by ERBB2 log2 ratio of at least 0.3. In both cohorts, triple-negative patients were defined using PAM50 Basal classification. Significance was determined using χ 2 test.
Generalized linear models. Associations in copy-number gain were estimated using a linear model taking into account parameters including PAM50 subtype, neoantigen load (53), overall copynumber aberration, immune content (54), and patient age.
Spatial, Diversity, and Statistical Analyses
Association between DCIS/IDC cell type, ERBB2, and chemokine cluster amplification. The association between the probability of a cell carrying the 17q12 CC amplification and ERBB2 amplification [together with the cell type (DCIS or IDC cells) in the DCIS/IDC cohorts] was estimated using logistic hierarchical model (or logistic mixed effects regression; ref. 55) to account for the correlation of cells within each sample and of samples within each patient. In addition, we adjusted for important clinical covariates collected in this study, including patients' ages, ER status, and others. The selection of covariates from those collected was justified using the Akaike Information Criterion (AIC; ref. 56 ). The models with the lowest AIC in both cohorts (AIC = 4412.2 in pure DCIS and 10909.7 in DCIS/ IDC) were selected as the final model to interpret (Supplementary  Table S5 ).
Diversity estimation from single-cell FISH data. To compute the diversity from the multicolor FISH data, we first categorized each cell into the following four types based on copy number for ERBB2 and the CC: ERBB2 + CC + , ERBB2 + CC − , ERBB2 − CC + , and ERBB2 − CC − . Next, the number of cells belonging to each category was determined and the Shannon's entropy (24) was thereby calculated for each sample of each patient. The association between the diversity and Cancer Research.
on November 2, 2017. © 2017 American Association for cancerdiscovery.aacrjournals.org Downloaded from patients' age was evaluated for both the pure DCIS and DCIS-IDC cohorts ( Supplementary Fig. S7I ). Interestingly, in the DCIS-IDC cohort, diversity was significantly associated with patients' age (P = 0.0183 for DCIS cell type and P = 0.0146 for IDC cell type), whereas there was no such association supported by statistical significance in the pure DCIS cohort. Furthermore, we also studied the association between diversity and CD3 and CD45 counts, and found no significant correlation between these two factors in both cohorts (Supplementary Fig. S7H ).
Spatial analyses.
We then considered another layer of information contained in the immuno-FISH images describing the spatial distribution of single cells. We sought to investigate the observed patterns relative to the null hypothesis-complete spatial randomness. Such analysis can help inform future evolutionary modeling of tumor development and intratumor heterogeneity. Here our definition of complete spatial randomness closely follows (57): (i) regardless of the type of cells, the cells are randomly localized on the 2-D slice of a tumor by a spatial uniform Poisson process with an intensity parameter estimated from all cells on the image; (ii) for each single cell, we randomly assign one of the four mutation types defined in the previous section based on the relative frequency of each mutation type, again estimated from the image. This approach is also called marked spatial Poisson process (58) . To test such complete spatial randomness, we first used Monte Carlo simulation to generate a number of simulated samples under the null hypothesis, and calculated the so-called "cross" K function (a function of the radius of the neighborhood of each cell; ref. 57) using both the simulated samples and the patient sample. With a collection of simulated samples, we then constructed a 95% confidence band of the K function and determined if the K function computed from the patient data lies within the 95% confidence band under complete spatial randomness, to investigate whether the spatial distribution of different cell types in 2-D deviates from the null hypothesis. Supplementary Figure S7F shows that most of the patient samples do not significantly deviate from the complete spatial randomness, demonstrated by the K function of the data (black curve) lying within the 95% confidence band of the K function of the simulated datasets (gray area).
Analysis of invasiveness of tumor cells and T cells.
Because of the relatively small number of cells subdivided by the TIGIT or PD-1 expression levels, we considered only the comparison between tumor cell populations and T-cell populations in the image. In Supplementary Fig. S6A , we used different colors to distinguish T cells (black for TIGIT + or PD-1
